Last updated: February 19, 2026
What is the current status of clinical trials for pegcetacoplan?
Pegcetacoplan (APL-2) is a complement C3 inhibitor developed by Apellis Pharmaceuticals. It targets complement-mediated diseases by inhibiting activation of the C3 component of the complement cascade.
Clinical Trial Phases and Progress
- Age-Related Macular Degeneration (AMD): Phase 3 trials (OAKS, DERBY) completed with positive results. Both studies demonstrated reduction in geographic atrophy (GA) lesion growth compared to sham. Approval submissions are underway.
- Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase 3 (PEGASUS) confirmed efficacy, with complete and partial responders showing improvements in hemolysis parameters. Regulatory submission occurred in 2022.
- Complement-mediated Rare Diseases: Early-phase trials target diseases like geographic atrophy and atypical hemolytic uremic syndrome (aHUS).
Recent Updates (2022–2023)
- The FDA accepted the novel drug application (NDA) for pegcetacoplan in GA, with a decision expected by late 2023.
- Data from ongoing open-label extensions indicate sustained efficacy and an acceptable safety profile.
How does the market landscape look for pegcetacoplan?
Market Size and Growth
- Age-Related Macular Degeneration (AMD): The global GA treatment market was valued at approximately USD 2.4 billion in 2022, expected to grow at a CAGR of 8% through 2030.[1]
- Paroxysmal Nocturnal Hemoglobinuria (PNH): The PNH therapy market was valued at USD 3.3 billion in 2021, projected to reach USD 4.8 billion by 2030, with pegcetacoplan capturing a significant share due to its efficacy.[2]
Competitive Landscape
- AMD: Limited approved therapies for GA. Roche's Roche's lampalizumab failed in Phase 3, and Apellis' pegcetacoplan is the first late-stage candidate.
- PNH: Eculizumab (by Alexion/Astellas) holds a dominant position but is administered intravenously, whereas pegcetacoplan offers subcutaneous delivery, potentially improving patient compliance.
Regulatory and Market Access Factors
- The FDA approval decision expands market access in the U.S., with European Medicines Agency (EMA) review underway.
- Reimbursement negotiations are active, with payers assessing value based on clinical benefit and pricing strategies.
What are the projections for pegcetacoplan’s market penetration and revenues?
Revenue Forecasts (2023–2030)
| Year |
Estimated Revenue (USD billion) |
Assumptions |
Source |
| 2023 |
0.1 |
Limited access post-approval; initial adoption in the U.S. |
Internal estimate |
| 2024 |
0.4 |
Growing awareness; expanded indications; initial European launches |
Internal estimate |
| 2025 |
0.8 |
Increased market penetration; payer coverage improves |
Internal estimate |
| 2026 |
1.4 |
Broader global access, additional indications |
Internal estimate |
| 2030 |
3.0 |
Leading position in AMD and PNH segments |
Internal estimate |
Key Success Factors
- Demonstration of long-term safety and efficacy.
- Competitive pricing and reimbursement deals.
- Expansion into additional indications like atypical hemolytic uremic syndrome.
What risks could affect the future outlook?
- Regulatory setbacks or delays.
- Competitive entrants with superior efficacy or delivery methods.
- Payer resistance in key markets.
- Manufacturing scalability and supply chain stability.
Key Takeaways
Pegcetacoplan continues progressing through late-stage development, with FDA submission imminent for AMD indication. The global markets for AMD and PNH present substantial growth opportunities, especially if regulatory approvals are granted. Market penetration will depend on clinical data, pricing strategies, reimbursement approvals, and competitive landscape advancements.
FAQs
What distinguishes pegcetacoplan from other complement inhibitors?
Pegcetacoplan inhibits the central complement component C3, effectively blocking multiple activation pathways. It is administered subcutaneously, offering a potential advantage over IV formulations like eculizumab.
When could pegcetacoplan be available commercially?
Approval in the U.S. is anticipated in late 2023 following FDA review. European and other markets could see launches in 2024–2025.
How does pegcetacoplan compare to lampalizumab for AMD?
Lampalizumab failed in Phase 3 trials. Pegcetacoplan has demonstrated efficacy in Phase 3 trials with sustained lesion reduction, positioning it as the leading candidate for GA treatment.
What are the primary safety concerns for pegcetacoplan?
Adverse events include injection site reactions, infections, and potential complement-related immune modulation effects. Long-term safety data are still accumulating.
Which companies are the main competitors to Apellis in the complement field?
Alexion/Astellas in PNH and atypical hemolytic uremic syndrome; other biotechs developing alternative complement inhibitors targeting different cascade points.
References
[1] MarketsandMarkets. (2022). Age-related Macular Degeneration (AMD) Market by Type, Treatment, and Region.
[2] Grand View Research. (2021). Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Size & Trends.
